When was Seattle Genetics founded?

Seattle Genetics was founded in 1998 and raised its 1st funding round within a year of its incorporation.

Where is Seattle Genetics located?

Seattle Genetics is headquartered in Bothell, United States.

How many employees does Seattle Genetics have?

As of Aug 31, 2026, the latest employee count at Seattle Genetics is 692.

Is Seattle Genetics a funded company?

Seattle Genetics is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on 1998.

When was the latest funding round of Seattle Genetics?

Seattle Genetics' latest funding was a $***** Post IPO round on Sep 14, 2020, with participation from 1 investor.

Where does Seattle Genetics rank among its competitors?

Seattle Genetics ranks 80th amongst 3318 active competitors, of which 1118 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Seattle Genetics?

Seattle Genetics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Seattle Genetics - 2026 Company Profile, Funding & Competitors

Q: Is Seattle Genetics an acquired company?

Seattle Genetics got acquired by Pfizer on Mar 13, 2023.

Company Details

Developer of antibody-drug conjugates for the treatment of cancer. The company's products include Brentuximab vedotin targets CD30 found on the surface of Hodgkin lymphoma cells, Enfortumab vedotin for bladder cancer, Tucatinib for multiple cancers, Tisotumab vedotin targets tissue factors on solid tumors, Ladiratuzumab vedotin targets LIV-1, and others.

Website: seagen.com
Social
Email ID: *****@seagen.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

1998

Location

Bothell, United States

Stage

Acquired

Latest Funding Round

Post IPO, Sep 14, 2020, $*****

Investors

J P Morgan & 12 more

Ranked

80^th among 3318 active competitors

Employee Count

692 as on Aug 31, 2026

Investment & Acquisitions

Pieris Pharmaceuticals & 1 more

Similar Companies

BeiGene & 565 more

Exit Details

Acquired by Pfizer (Mar 13, 2023)

View Seattle Genetics' full profile

Seattle Genetics is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Seagen CIN: 40203129016 , Latvia, Active	Mar 07, 2018	€0 - €1M (As on Dec 31, 2020)	1 (As on Dec 31, 2022)	-
SEATTLE GENETICS INC /WA CIN: 1060736 , United States, Active		$1B+ (As on Dec 31, 2022)	14 (As on Jun 30, 2021)	-
Seagen Inc CIN: 91-1874389 , United States, Active	Jul 14, 1997	-	3256 (As on Dec 31, 2022)	-
Seagen Denmark ApS CIN: 40738576 , Denmark, Active	Aug 25, 2019	-	3 (As on Dec 31, 2023)
Seagen Inc. CIN: 911874389 , United States, Active	Jul 14, 1997	-	3297 (As on Dec 31, 2023)	-

Seattle Genetics got acquired by Pfizer on Mar 13, 2023 at an acquisition amount of $*****.

Click here to take a look at Seattle Genetics's acquisition in detail

Seattle Genetics has raised funding over 6 rounds. Its first funding round was on 1998. Its latest funding round was a Post IPO round on Sep 14, 2020 for $*****. 1 investor participated in its latest round. Seattle Genetics has 13 institutional investors.

Here is the list of recent funding rounds of Seattle Genetics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 14, 2020	3968650	Post IPO	7608296	3362407	9245996	7096827
Jan 2014	3322053	Post IPO	7993206	4565805	7517827	Takeda
2009	5139	Post IPO	7024	3537	7520	New Enterprise Associates

Access funding benchmarks and valuations. Sign up today!

View details of Seattle Genetics's funding rounds and investors

Seattle Genetics' employee count trend

Seattle Genetics has 692 employees as of Aug 26. Here is Seattle Genetics's employee count trend over the years:

Employee count trend for Seattle Genetics

Uncover Seattle Genetics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Seattle Genetics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Seattle Genetics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
80th	Seattle Genetics 1998, Bothell (United States), Acquired	Developer of antibody-drug conjugates for the treatment of cancer	-	T. Rowe Price, Takeda & 11 others	64/100